Proton magnetic resonance spectroscopy in schizophrenia

European Journal of Radiology

Volumn 30, Issue 2, 1999, Pages 132-141

  Bertolino, Alessandro ^a   Weinberger, Daniel R ^a  

^a Intramural Research Program   (United States)

Author keywords

Magnetic resonance spectroscopy; Schizophrenia; Spectral localization

Indexed keywords

BEHAVIORAL RESEARCH; BRAIN; NEUROPHYSIOLOGY; PSYCHOPHYSIOLOGY;

SCHIZOPHRENIA;

MAGNETIC RESONANCE SPECTROSCOPY;

CHOLINE; CREATINE; N ACETYLASPARTIC ACID;

ARTICLE; HUMAN; METABOLITE; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

BRAIN; BRAIN CHEMISTRY; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; PROTONS; SCHIZOPHRENIA;

EID: 0033013591     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0720-048X(99)00052-2     Document Type: Article

References (55)

1. Urenjak J., Williams S.R., Gadian D.G., Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J. Neurosci. 13:1993;981-989.
2. Moffett J.R., Namboodiri M.A. Differential distribution of N-acetylaspartylglutamate and N-acetylaspartate immunoreactivities in rat forebrain. J. Neurocytol. 24:1995;409-433.
3. Clark J.B. N-acetyl aspartate: a marker for neuronal loss or mitochondrial dysfunction. Dev. Neurosci. 20:1998;271-276.
4. Rubin Y., LaPlaca M.C., Smith D.H., Thibault L.E., Lenkinski R.E. The effect of N-acetyl-aspartate on the intracellular calcium concentration in NTera2-neurons. Neurosci. Lett. 198:1995;209-212.
5. 1H MRS studies. Neuroreport. 7:1996;1397-1400.
6. Cendes F., Andermann F., Dubeau F., Matthews P.M., Arnold D.L. Normalization of neuronal metabolic dysfunction after surgery for temporal lobe epilepsy. Evidence from proton MR spectroscopic imaging. Neurology. 49:1997;1525-1533.
7. De Stefano N., Matthews P., Antel J.P., Preul M., Francis G., Arnold D.L. Chemical pathology of acute demyelinating lesions and its correlations with disability. Ann. Neurol. 38:1995;901-909.
8. Vion-Dury J., Salvan A.M., Confort-Gouny S., Dhiver C., Cozzone P. Reversal of brain metabolic alterations with zidovudine detected by proton localised magnetic resonance spectroscopy. Lancet. 345:1995;60-61.
9. 1H magnetic resonance spectroscopic imaging. Ann. Neurol. 40:1996;236-239.
10. Barker P.B., Breiter S.N., Soher B.J., Chatham J.C., Forder J.R., Samphilipo M.A., Magee C.A., Anderson J.H. Quantitative proton spectroscopy of canine brain: in vivo and in vitro correlations. Magn. Reson. Med. 32:1994;157-163.
11. 1H NMR spectroscopy: N-Acetyl-L-aspartate, creatine and choline. NMR Biomed. 4:1991;47-52.
12. 1H MR spectra. Magn. Reson. Med. 34:1995;17-24.
13. Shulman R.G., Rothman D.L. Interpreting functional imaging studies in terms of neurotransmitter cycling. PNAS. 95:1998.
14. 1 MR spectroscopy. Radiology. 182:1992;19-27.
15. Weinberger D.R. From neuropathology to neurodevelopment. Lancet. 346:1995;552-557.
16. Weinberger D.R., Lipska B.K. Cortical maldevelopment, antipsychotic drugs, and schizophrenia: a search for common ground. Schizophrenia Research. 16:1995;87-110.
17. Nasrallah H.A., Skinner T.E., Schmalbrock P., Robitaille P.M. Proton magnetic resonance spectroscopy of the hippocampal formation in schizophrenia: a pilot study. Br. J. Psychiatry. 165:1994;481-485.
18. Renshaw P.F., Yurgelun-Todd D.A., Tohen M.S.G.B.M.C. Temporal lobe proton magnetic resonance spectroscopy of patients with first-episode psychosis. Am. J. Psychiatry. 152:1995;444-446.
19. Yurgelun-Todd D.A., Renshaw P.F., Gruber S.A., Waternaux C.M., Cohen B.M. Proton magnetic resonance spectroscopy of the temporal lobes in schizophrenics and normal controls. Schizophr. Res. 19:1996;55-59.
20. 1H Magnetic resonance spectroscopy of the left temporal and frontal lobes in schizophrenia: clinical neurodevelopmental and cognitive correlates. Biol. Psychiatry. 36:1994;792-800.
21. Maier M., Ron M.A., Barker G.J., Tofts P.S. Proton magnetic resonance spectroscopy: an in vivo method of estimating hippocampal neuronal depletion in schizophrenia. Psychol. Med. 25:1995;1201-1209.
22. Maier M., Ron M.A. Hippocampal age-related changes in schizophrenia: a proton magnetic resonance spectroscopy study. Schizophr. Res. 22:1996;5-17.
23. Fukuzako H., Takeuchi K., Hokazono Y., Fukuzako T., Yamada K., Hashiguchi T., Obo Y., Ueyama K., Takigawa M., Fujimoto T. Proton magnetic resonance spectroscopy of the left medial temporal and frontal lobes in chronic schizophrenia: preliminary report. Psychiatry Res. Neuroimag. 61:1995;193-200.
24. Stanley J.A., Williamson P.C., Drost D.J., Rylett R.J., Carr T.J., Malla A., Thompson R.T. An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients. Schizophr. Bull. 22:1996;597-609.
25. Bartha R., Williamson P.C., Drost D.J., Malla A., Carr T.J., Cortese L., Canaran G., Rylett R.J., Neufeld R.W. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry. 54:1997;959-965.
26. Bertolino A., Callicott J.H., Nawroz S., Mattay V.S., Duyn J.H., Tedeschi G., Frank J.A., Weinberger D.R. Reproducibility of proton magnetic resonance spectroscopic imaging in patients with schizophrenia. Neuropsychopharmacology. 18:1998;1-9.
27. Cecil K.M., Lenkinski R.E., Gur R.E., Gur R.C. Proton magnetic resonance spectroscopy in the frontal and temporal lobes of neuroleptic naive patients with schizophrenia. Neuropsychopharmacology. 20:1998;131-140.
28. 1H-MRS. Biological Psychiatry. Washington, DC, 1999.
29. Brooks W.M., Hodde-Vargas J., Vargas L.A., Yeo R.A., Ford C.C., Hendren R.L. Frontal lobe of children with schizophrenia spectrum disorders: a proton magnetic resonance spectroscopic study. Biol. Psychiatry. 43:1998;263-269.
30. 1H MR spectroscopy in childhood-onset schizophrenia. Magn. Reson. Imaging. 84:1998;841-846.
31. Sharma R., Venkatasubramanian P.N., Barany M., Davis J.M. Proton magnetic resonance spectroscopy of the brain in schizophrenic and affective patients. Schizophr. Res. 81:1992;43-49.
32. Shioiri T., Hamakawa H., Kato T., Murashita J., Fuji K., Inubushi T., Takahasji S. Proton magnetic resonance spectroscopy of the basal ganglia in patients with schizophrenia: a preliminary report. Schizophr. Res. 22:1996;19-26.
33. Fujimoto T., Nakano T., Takano T., Takeuchi K., Yamada K., Fukuzako T., Akimoto H. Proton magnetic resonance spectroscopy of basal ganglia in chronic schizophrenia. Biol. Psychiatry. 40:1996;14-18.
34. Heimberg C., Komoroski R., Lawson W.B., Cardwell D., Karson C. Regional proton magnetic resonance spectroscopy in schizophrenia and exploration of drug effect. Psychiatry Res.: Neuroimag. 83:1998;105-115.
35. Eluri R., Paul C., Roemer R., Boyko O. Single-voxel proton magnetic resonance spectroscopy of the pons and cerebellum in patients with schizophrenia: a preliminary study. Psychiatry Res.: Neuroimag. 84:1998;17-26.
36. Duyn J.H., Gillen J., Sobering G., van Zijl P.C., Moonen C.T.W. Multisection proton MR spectroscopic imaging of the brain. Radiology. 188:1993;277-282.
37. Bertolino A., Nawroz S., Mattay V.S., Duyn J.H., Moonen C.T.W., Barnett A.S., Frank J.A., Tedeschi G., Weinberger D.R. A specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. Am. J. Psychiatry. 153:1996;1554-1563.
38. Bertolino A., Callicott J.H., Elman I., Mattay V.S., Tedeschi G., Frank J.A., Breier A., Weinberger D.R. Regionally specific neuronal pathology in untreated patients with schizophrenia: a proton magnetic resonance spectroscopic imaging study. Biol. Psychiatry. 43:1998;641-648.
39. Bertolino A., Kumra S., Callicott J.H., Mattay V.S., Lestz R.M., Jacobsen L., Barnett A.S., Duyn J.H., Frank J.A., Rapoport J.L., Weinberger D.R. Common pattern of cortical pathology in childhood-onset and adult-onset schizophrenia as identified by proton magnetic resonance spectroscopic imaging. Am. J. Psychiatry. 155:1998;1376-1383.
40. Callicott J.H., Egan M.F., Bertolino A., Mattay V.S., Langheim F.J.P., Frank J.A., Weinberger D.R. Hippocampal N-acetylaspartate in unaffected siblings of patients with schizophrenia: a possible intermediate phenotype. Biol. Psychiatry. 44:1998;941-950.
41. Langheim F.J.P., Callicott J.H., Bertolino A., Mattay V.S., Weinberger D.R. Clinical correlates between proton MR spectroscopic abnormalities and negative symptoms in patients with schizophrenia. Neuroimage. 7:1998;284.
42. Deicken R.F., Zhou L., Corwin F., Vinogradov S., Weiner M.W. Decreased left frontal lobe N-Acetylaspartate in schizophrenia. Am. J. Psychiatry. 154:1997;688-690.
43. Deicken R.F., Zhou L., Schuff N., Fein G., Weiner M.W. Hippocampal neuronal dysfunction in schizophrenia as measured by proton magnetic resonance spectroscopy. Biol. Psychiatry. 43:1998;483-488.
44. Deicken R.F., Zhou L., Schuff N., Weiner M.W. Proton magnetic resonance spectroscopy of the anterior cingulate region in schizophrenia. Schizophr. Res. 27:1997;65-71.
45. Lim K.O., Adaksteinsson E., Spielman D., Sullivan E., Rosenbloom M.J., Pfefferbaum A. Proton magnetic resonance spectroscopic imaging of cortical gray and white matter in schizophrenia. Arch. Gen. Psychiatry. 55:1998;362-364.
46. Bertolino, A, Knable MB, Saunders RC, Callicott JH, Kolachana BS, Mattay VS, Bachevalier J, Egan MF, Frank JA, Weinberger DR. The relationship between dorsolateral prefrontal N-acetylaspartate measures and striatal dopamine activity in schizophrenia. Biol Psychiatry 1999.
47. Bertolino A., Breier A., Callicott J.H., Adler C., Mattay V.S., Shapiro M., Frank J.A., Pickar D., Weinberger D.R. The relationship between prefrontal neuronal integrity and striatal amphetamine-induced dopamine activity in patients with schizophrenia. Neuroimage. 7:1998;31.
48. 1H-MRSI correlates with rCBF activation during working memory in patients with schizophrenia. Neuroimage. 5:1997;281.
49. Bertolino A., Saunders R.C., Mattay V.S., Bachevalier J., Frank J.A., Weinberger D.R. Proton magnetic resonance spectroscopic imaging in monkeys with mesial temporo-limbic lesions. Cerebral Cortex. 7:1997;740-748.
50. 1H-MRS study. Biological Psychiatry. Washington, DC, 1999.
51. Tedeschi G., Bertolino A., Lundbom N., Bonavita S., Patronas N.J., Duyn J.H., Metman L.V., Chase T.N., Di Chiro G. Cortical and subcortical chemical pathology in Alzheimer's disease as assessed by multislice proton magnetic resonance spectroscopic imaging. Neurology. 47:1996;696-704.
52. Najim I.M., Wang Y., Shedid D., Luders H.O., Ng T.C., Comair Y.G. MRS metabolic markers of seizures and seizure-induced neuronal damage. Epilepsia. 39:1998;244-250.
53. Akbarian S., Sucher N.J., Bradley D., Tafazzoli A., Trinh D., Hetrick W.P., Potkin S.G., Sandman C.A., Bunney W.E.J., Jones E.G. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J. Neurosci. 16:1996;19-30.
54. Eastwood S.L., McDonald B., Burnet P.W., Beckwith J.P., Kerwin R.W., Harrison P.J. Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia. Mol. Brain Res. 29:1995;211-223.
55. Goldman-Rakic P.S. Handbook of Physiology: The Nervous System. 1987;American Physiological Society, Bethesda, MD.